Alexza Pharmaceuticals, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2001-01-01
- Employees
- 51
- Market Cap
- -
- Website
- http://www.alexza.com
Staccato Prochlorperazine in Migraine (in Clinic)
Phase 2
Completed
- Conditions
- Migraine Headache, With or Without Aura
- Interventions
- First Posted Date
- 2008-02-08
- Last Posted Date
- 2018-01-25
- Lead Sponsor
- Alexza Pharmaceuticals, Inc.
- Target Recruit Count
- 75
- Registration Number
- NCT00610428
- Locations
- 🇺🇸
Arthur H. Elkind, MD, Mount Vernon, New York, United States
Staccato Alprazolam Abuse Liability
Phase 1
Completed
- Conditions
- Abuse Liability of Staccato Alprazolam
- Interventions
- Drug: Inhaled placebo + oral placeboDrug: Inhaled alprazolam 0.5 mgDrug: Oral alprazolam 4 mDrug: Oral alprazolam 2 mg qualifying sessionDrug: Oral placebo qualifying session
- First Posted Date
- 2008-01-29
- Last Posted Date
- 2020-01-02
- Lead Sponsor
- Alexza Pharmaceuticals, Inc.
- Target Recruit Count
- 31
- Registration Number
- NCT00603980
- Locations
- 🇺🇸
Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
Staccato Loxapine Multidose PK
Phase 1
Completed
- Conditions
- Volunteers on Chronic, Stable Antipsychotic Regimens
- Interventions
- Drug: B - 10 mg x 1, 5 mg x 2 loxapine q 4 h (20 mg total)Drug: A - 10 mg loxapine q 4 h x 3 (30 mg total)Drug: C - 5 mg loxapine q 4 h x 3 (15 mg total)
- First Posted Date
- 2007-11-08
- Last Posted Date
- 2017-03-15
- Lead Sponsor
- Alexza Pharmaceuticals, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT00555412
- Locations
- 🇺🇸
Atlanta Center for Medical Research, Atlanta, Georgia, United States
Staccato Prochlorperazine Thorough QT/QTc
Phase 1
Completed
- Conditions
- Cardiotoxicity
- Interventions
- Drug: Inhaled placeboDrug: Oral placebo
- First Posted Date
- 2007-10-12
- Last Posted Date
- 2019-03-11
- Lead Sponsor
- Alexza Pharmaceuticals, Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT00543062
- Locations
- 🇺🇸
Covance Clinical Research Unit Inc., Evansville, Indiana, United States
Staccato Loxapine in Migraine (in Clinic)
Phase 2
Completed
- Conditions
- Migraine
- Interventions
- Drug: Staccato LoxapineDrug: Staccato Placebo
- First Posted Date
- 2007-06-21
- Last Posted Date
- 2017-07-06
- Lead Sponsor
- Alexza Pharmaceuticals, Inc.
- Target Recruit Count
- 168
- Registration Number
- NCT00489476
- Locations
- 🇺🇸
Medvadis, Wellesley Hills, Massachusetts, United States
Staccato Alprazolam in Panic Attack
Phase 2
Completed
- Conditions
- Treatment of Induced Panic Attack
- Interventions
- First Posted Date
- 2007-05-23
- Last Posted Date
- 2017-06-16
- Lead Sponsor
- Alexza Pharmaceuticals, Inc.
- Target Recruit Count
- 49
- Registration Number
- NCT00477451
- Locations
- 🇺🇸
SUNY Downstate Medical Center, Brooklyn, New York, United States
🇺🇸New York State Psychiatric Institute, New York, New York, United States
🇺🇸Mt. Sinai School Of Medicine, New York, New York, United States
Staccato Alprazolam Single Dose PK
Phase 1
Completed
- Conditions
- Healthy
- First Posted Date
- 2007-03-08
- Last Posted Date
- 2017-03-14
- Lead Sponsor
- Alexza Pharmaceuticals, Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT00444522
Staccato Loxapine Single Dose PK
Phase 1
Completed
- Conditions
- Schizophrenia
- Interventions
- Drug: inhaled Loxapine 0.625 mgDrug: inhaled Loxapine 1.25 mgDrug: inhaled Loxapine 2.5 mgDrug: inhaled Placebo (0 mg)
- First Posted Date
- 2007-03-07
- Last Posted Date
- 2018-11-20
- Lead Sponsor
- Alexza Pharmaceuticals, Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT00444028
- Locations
- 🇺🇸
Covance Clinical Research Unit Inc., d/b/a Covance GFI Research, Evansville, Indiana, United States
Staccato Prochlorperazine in Migraine (Out Patient)
Phase 2
Completed
- Conditions
- Migraine HeadacheAura
- Interventions
- Drug: Inhaled PCZ 7.5 mgDrug: Inhaled PCZ 5 mgDrug: Inhaled PlaceboDrug: Inhaled PCZ 10 mg
- First Posted Date
- 2007-01-17
- Last Posted Date
- 2018-01-25
- Lead Sponsor
- Alexza Pharmaceuticals, Inc.
- Target Recruit Count
- 400
- Registration Number
- NCT00422812
- Locations
- 🇺🇸
Palm Beach Neurological Center, West Palm Beach, Florida, United States
🇺🇸The New England Center for Headache, Stamford, Connecticut, United States
🇺🇸Department of Neurology, Mayo Clinic, Scottsdale, Arizona, United States
Staccato Fentanyl Single and Multidose PK
Phase 1
Completed
- Conditions
- Breakthrough Pain
- Interventions
- Drug: Inhaled PlaceboDrug: Inhaled Fentanyl 25 mcgDrug: Inhaled Fentanyl 25 mcg x 2Drug: Inhaled Fentanyl 25 mcg x 4Drug: Inhaled Fentanyl 25 mcg x 6Drug: Inhaled Fentanyl 25 mcg x 12Drug: Intravenous Fentanyl 25 mcg
- First Posted Date
- 2006-11-22
- Last Posted Date
- 2017-03-15
- Lead Sponsor
- Alexza Pharmaceuticals, Inc.
- Target Recruit Count
- 51
- Registration Number
- NCT00402350
- Locations
- 🇺🇸
Duke University, Durham, North Carolina, United States
© Copyright 2025. All Rights Reserved by MedPath